Follow-up After Percutaneous Radiofrequency Ablation of Renal Cell Carcinoma: Contrast-enhanced Sonography Versus Contrast-enhanced CT or MRI
Overview
Authors
Affiliations
Objective: The purpose of this study was to assess, with contrast-enhanced CT or MRI as the reference imaging technique, the diagnostic performance of low-mechanical-index contrast-enhanced sonography in detecting local tumor progression after percutaneous radiofrequency ablation of renal tumors.
Materials And Methods: Twenty-nine patients with 30 renal tumors (18 men, 11 women; mean age, 73 years; range, 53-83 years) underwent percutaneous radiofrequency ablation at a single center between March 1998 and January 2007. The imaging follow-up schedule was both contrast-enhanced sonography and CT or MRI 4 months after completion of treatment and every 4 months for the first year. Thereafter, the follow-up schedule was contrast-enhanced sonography every 4 months with CT or MRI every 8 months. The chi-square test with Yates correction was used to evaluate positive and negative predictive values and accuracy.
Results: One patient was scheduled to undergo surgical resection, and another patient was lost to follow-up. Twenty-seven patients with 28 renal tumors participated in follow-up. The concordance between contrast-enhanced sonographic and CT or MRI findings was 100% for 27 of 28 tumors (96.4%) that had a hypervascular pattern before treatment. In the case of the tumor that was hypovascular at imaging performed before percutaneous radiofrequency ablation, local tumor progression was missed at contrast-enhanced sonography. The sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy of contrast-enhanced sonography were 96.6%, 100%, 100%, 95.8%, and 98.1%.
Conclusion: Contrast-enhanced sonography is an effective alternative to CT and MRI in the follow-up of renal tumors managed with percutaneous radiofrequency ablation.
Ablative Treatments for Small Renal Masses and Management of Recurrences: A Comprehensive Review.
Aveta A, Iossa V, Spena G, Conforti P, Pagano G, Dinacci F Life (Basel). 2024; 14(4).
PMID: 38672721 PMC: 11050889. DOI: 10.3390/life14040450.
Role of Contrast-Enhanced Ultrasound (CEUS) in Native Kidney Pathology: Limits and Fields of Action.
Granata A, Campo I, Lentini P, Pesce F, Gesualdo L, Basile A Diagnostics (Basel). 2021; 11(6).
PMID: 34201349 PMC: 8226824. DOI: 10.3390/diagnostics11061058.
Systematic review of ablative therapy for the treatment of renal allograft neoplasms.
Favi E, Raison N, Ambrogi F, Delbue S, Clementi M, Lamperti L World J Clin Cases. 2019; 7(17):2487-2504.
PMID: 31559284 PMC: 6745334. DOI: 10.12998/wjcc.v7.i17.2487.
Clinical application of contrast-enhanced ultrasound after percutaneous renal tumor ablation.
Guo F, Hu B, Chen L, Li J Br J Radiol. 2019; 92(1103):20190183.
PMID: 31509441 PMC: 6849667. DOI: 10.1259/bjr.20190183.
Contrast-enhanced ultrasonography in interventional oncology.
Gummadi S, Eisenbrey J, Lyshchik A Abdom Radiol (NY). 2018; 43(11):3166-3175.
PMID: 29632993 PMC: 6276786. DOI: 10.1007/s00261-018-1581-5.